iDetect KC

Keratoconus care starts with optometry

The iDetect KC program makes advanced topography more accessible than ever before. For a fraction of the price, optometrists can bring this essential diagnostic tool into their practice so they can:

  • Quickly and easily take the lead in identifying keratoconus earlier
  • Contribute to scientific advancements through the iDetect KC data registry
  • Offer FDA-approved treatments to manage, slow, or halt progressive keratoconus
  • Provide lifelong care and expertise for patients

Get more information about iDetect KC

Get Started
Topcon CA-800 Topographer display screen.

Earlier keratoconus detection is key

Evidence suggests more patients could benefit from earlier identification of their sight-threatening keratoconus.

70%
of keratoconus presents
through optometry. 1
An illustration of a doctor and a patient.

Early onset: The vast majority of cases present between 12 and 20 years of age. Onset may also occur at birth and up to 51 years of age.2

Illustration of an eye.

Keratoconus is a rare and sight-threatening disease, US prevalence has been reported to be 1 in 2000.7

The power of trusted topography

iDetect KC equips optometrists with advanced topography so they can implement the 3 pillars of modern keratoconus care into their practice.

1. Early diagnosis & monitoring
arrow down direction

A topographer can help optometrists:

Identify keratoconus
patients sooner

Monitor keratoconus progression

Preserve vision with
earlier intervention

Confidently refer patients to
an ophthalmologist for
treatment with iLink®

arrow up direction
2. Slow or halt progression
arrow down direction

The iLink® corneal cross-linking procedure:

Slows or halts progressive keratoconus

Is proven safe and effective5

Is eligible for commercial
insurance coverage

arrow up direction
3. Patient retention
arrow down direction

Topography enables
optometrists to:

Provide long-term care for patients

Expand their contact lens service

arrow up direction

A paradigm shift in diagnostic accuracy and
keratoconus treatment and management

With access to advanced topography, optometrists can have greater confidence in their assessments, a simplified diagnostic and treatment journey, and more control over the patient experience.

Bring advanced topography into your practice

Learn More Watch Videos
standout-card-icon

The iDetect KC Program

Glaukos and Topcon have partnered to offer optometrists the advanced technology of the Topcon CA-800 topographer at a lower cost of entry.

The Topcon CA-800 Topographer

Key features and benefits6:

  • Placido-based topography delivers complete anterior corneal surface evaluation for early detection
  • Advanced keratoconus probability index indicates likelihood of keratoconus through analysis of apical curvature, apical gradient, and symmetry of the cornea
  • Easy serial follow-up on keratoconus and keratoconus-like patterns
    Diagnostic capabilities for various common ocular pathologies, including detailed dry eye measurements

A win for the keratoconus community

The iDetect KC data registry makes it easy to leave a lasting impact on the future of keratoconus care by uploading data from:

  • Potential keratoconus patients
  • Post-op iLink® patients
topcon
topcon

Ready to experience the many lifelong benefits of the iDetect KC program?

Complete the form below to find out more and we will be in touch with you shortly.

"*" indicates required fields

Name*
Address*
Glaukos will use the information you provide on this form to be in touch with you.*
This field is for validation purposes and should be left unchanged.
contact-form-card-icon

Next-level
keratoconus care
is here

Confirming a progressive keratoconus diagnosis sooner can help preserve patients’ vision by providing them with treatment options, including iLink®—the only FDA-approved cross-linking treatment for the condition.

References

    1. Eisenberg JS. First treatment for keratoconus itself. Optometry Times. June 1, 2012. Accessed September 30, 2020. https://www.optometrytimes.com/view/first-treatment-keratoconus-itself
    2. Valdez-Garcia JE, Supúlveda R, Salazar-Martínez JJ, Lozano-Ramírez JF. Prevalence of keratoconus in an adolescent population. Revista Mexicana Oftalmologia. 2014;88:95-98.
    3. Godefrooij D, De Wit G, Uiterwaal C, et al. Age-specific incidence and prevalence of keratoconus: a nationwide registration study. Am J Ophthalmol. 2017;175:169-172.
    4. Hashemi H, Beiranvand A, Khabazkhoob M, Asgari S, Emamian MH, Shariati M, Fotouhi A. Prevalence of keratoconus in a population-based study in Shahroud. Cornea. 2013;32(11):1441-1445.
    5. Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016.
    6. CA-800 Corneal Analyzer. Topcon Medical Systems Inc. 2017.
    7. Kennedy RH, Bourne WM, Dyer JA. A 48-year clinical and epidemiologic study of keratoconus. Am J Ophthalmol. 1986;101(3):267-273.

Please Select Your Country

Continue

Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® System, the iLink® corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1

[Photrexa IFU/p1/col1/para3/lines1-4]

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, go to Prescribing Info to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

Indications

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Reference

1. Photrexa Prescribing Information. Burlington, MA: Avedro, a Glaukos company 2022

View Prescribing Information